Who owns Definium Therapeutics, Inc. (DFT)? Elite investor 13F holders
4 tracked elite investors reported holding Definium Therapeutics, Inc as of 2026-06-30, including Duquesne Family Office, D.E. Shaw, Gotham Asset Management, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Duquesne Family Office | Definium Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 16774000.00 USD | 356600.000000 | Shares | buy | Original filing |
| D.E. Shaw | Definium Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 14836887.00 USD | 315410.000000 | Shares | add | Original filing |
| Gotham Asset Management | Definium Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 207540.00 USD | 4412.000000 | Shares | buy | Original filing |
| Ancora Advisors / Ancora Holdings | Definium Therapeutics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 12136.00 USD | 258.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.